《法制日报》指控英国制药商葛兰素史克 逃税至少1亿元人民币。此前葛兰素史克高管人员被控行贿,该报导更增加了该公司面临的压力。

中国警方上周三表示,他们已经对葛兰素史克公司中国业务的前任老板和其他员工提起了指控,这已成为继2009年力拓公司(Rio Tinto)4名高管被捕入狱后中国外资公司最大的腐败丑闻。

尽管贿赂指控针对的是高管,而非公司本身,但中国媒体持续增加的指责暗示葛兰素史克远远没有度过安全期。

《法制日报》上周五报导称,葛兰素史克故意以较高成本进口拉米夫定(Lamivudine)。该药物用来治疗艾滋病和肝炎。

报导称,除了利用税收漏洞进行慈善捐款,此举还帮助葛兰素史克避免支付超过1亿元的进口增值税和企业所得税。

新华社此前发表的文章称,葛兰素史克使用转让定价人为降低其在中国的利润和税收。

尽管路透上周五以来多次致电、或通过短信和电子尝试与其联系,葛兰素史克在上海和伦敦的官员均拒绝置评。葛兰素史克上周三表示,贪污指控“十分可耻," 希望能圆满解决,使其继续为中国消费者服务。

Related Articles

China regulator 'to launch probe into foreign, local drug firms'

by Brenda Goh, Reuters |

China's price regulator plans to launch a "large-scale and systematic" anti-trust investigation soon into foreign and local drug firms, state newspaper China Daily said, citing a source close to the regulator.

China regulator probes Dutch firm IMC on futures trading

by Reuters |

Dutch high-speed trading firm IMC said on Thursday that China's securities regulator is investigating its trading activity in the Chinese futures market.

AgBank fine shows China banks still flunking compliance test

by Reuters |

Last week's $215 million fine for Agricultural Bank of China Ltd (AgBank), the third big Chinese bank disciplined by U.S. regulators in 16 months, shows Chinese lenders still falling short in their compliance duties.